TrialAmerican journal of hematology2017

Akt inhibitor MK-2206 in combination with bendamustine and rituximab in relapsed or refractory chronic lymphocytic leukemia: Results from the N1087 alliance study.

Jeremy T Larsen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.